ArticleJournal of imaging2026
ADAM-Net: Anatomy-Guided Attentive Unsupervised Domain Adaptation for Joint MG Segmentation and MGD Grading.
Article in Journal of imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Meibomian gland dysfunction (MGD) is a leading cause of dry eye disease, assessable through gland atrophy degree. While deep learning (DL) has advanced meibomian gland (MG) segmentation and MGD classification, existing methods treat these tasks independently and suffer from domain shift across multi-center imaging devices. We propose ADAM-Net, an attention-guided unsupervised domain adaptation multi-task framework that jointly models MG segmentation and MGD classification. Our model introduces structure-aware multi-task learning and anatomy-guided attention to enhance feature sharing, suppress background noise, and improve glandular region perception. For the cross-domain tasks MGD-1K→{K5M, CR-2, LV II}, this study systematically evaluates the overall performance of ADAM-Net from multiple perspectives. The experimental results show that ADAM-Net achieves classification accuracies of 77.93%, 74.86%, and 81.77% on the target domains, significantly outperforming current mainstream unsupervised domain adaptation (UDA) methods. The F1-score and the Matthews correlation coefficient (MCC-score) indicate that the model maintains robust discriminative capability even under class-imbalanced scenarios. t-SNE visualizations further validate its cross-domain feature alignment capability. These demonstrate that ADAM-Net exhibits strong robustness and interpretability in multi-center scenarios and provide an effective solution for automated MGD assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.